

Termination of discussions with Yesod Bio-Sciences Limited (“Yesod”)

28 Feb 2020

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

For immediate release

Redx Pharma plc

(“Redx” or the “Company”)

Termination of discussions with Yesod Bio-Sciences Limited (“Yesod”)

Alderley Park, 28 February 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis notes the announcement made earlier this afternoon by Yesod that it does not intend to make an offer for the entire issued and to be issued share capital of Redx pursuant to Rule 2.7 of the Code.

The Board of Redx decided, after careful consideration, including extensive discussion with Moulton Goodies Limited, the Company’s largest shareholder, that the possible offer from Yesod substantially undervalued the Company and its assets.

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469
920

Iain Ross, Chairman of the Redx Board of Directors

Lisa Anson, Chief Executive Officer

James Mead, Chief Financial Officer

Cantor Fitzgerald Europe (Nominated Adviser & Joint Broker)

T: +44 20 7894
7000

Phil Davies

WG Partners LLP (Joint Broker and Financial Adviser)

T: +44 20 3705
9330

Claes Spång/Chris Lee/David Wilson

FTI Consulting

T: +44 20 3727
1000

Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx is a UK based biotechnology company whose shares are traded on AIM ([AIM:REDX](#)). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link <https://www.redxpharma.com/investors/email-alerts/>

Notices related to financial adviser

Cantor Fitzgerald Europe, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Redx Pharma and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Redx Pharma for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement.

WG Partners LLP, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Redx Pharma and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Redx Pharma for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement.